FORCING 💊 (Dapagliflozin) Dapagliflozin - Review, diabetes mellitus

Clinical and pharmacological group: Oral - hypoglycemic drug
Active substance
dapagliflozin (dapagliflozin)

Indications:

Type 2 diabetes mellitus in addition to diet and exercise to improve glycemic control as:

monotherapy;
combination therapy with metformin, sulfonylurea derivatives (incl. in combination with metformin), thiazolidinediones, dipeptidyl peptidase 4 inhibitors (DPP-4) (incl. in combination with metformin), glucagon-like polypeptide-1 receptor agonist (GLP-1) exenatide of prolonged action in combination with metformin, insulin preparations (in incl. in combination with one or two hypoglycemic drugs for oral administration) in the absence of adequate glycemic control on this therapy;
starting combination therapy with metformin, if this therapy is appropriate.
Contraindications
increased individual sensitivity to any component of the drug;
type 1 diabetes mellitus;
diabetic ketoacidosis;
renal insufficiency with calculated GFR consistently less than 45 ml/min / 1.73 m2, including severe renal insufficiency and end-stage renal insufficiency;
pregnancy;
breastfeeding period;
age under 18 (safety and efficacy have not been studied);
patients taking "loop" diuretics, or with reduced BCC, for example, due to acute diseases (such as gastrointestinal diseases);
elderly patients aged 75 years and older (to start therapy);
hereditary lactose intolerance, lactase deficiency or glucose-galactose malabsorption.